Stockreport

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc.  (TSHA) 
PDF Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Recei [Read more]